MHLW approves two gene therapies in Japan
The two items approved were Anges Co. HGF gene therapy for treatment of critical limb ischemia (AMG0001, beperminogene perplasmid) Novartis CAR-T cell therapy Kymriah (Tisagenlecleucel) for the treatment of acute lymphoblastic B-cell leukemia Nikkei Biotech news release, February 21, 2019